Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03532555
Other study ID # 102434
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date March 22, 2018
Est. completion date August 25, 2022

Study information

Verified date January 2022
Source University of Utah
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Multiple factors contribute to growth failure in infants with BPD, including poor nutrient stores, inadequate intake, increased losses, and increased needs. Furthermore, compared to infants without BPD, those with BPD have increased resting metabolic rates and energy expenditure. Growth deficits manifest as lower weight, length, and head circumference, as well as changes in body composition. These deficits precede the development of BPD and persist post-discharge. While similar rates of growth are observed in very low birth weight infants with and without BPD once receiving equal calories, catch up growth does not occur in the BPD group. Thus, early growth deficits remained uncompensated. After iron, zinc is the most metabolically active trace element in the human body. It has a critical role in growth, through its actions on growth hormone, IGF-1, IGFBP-3, and bone metabolism. Prematurity is a risk factor for zinc deficiency, as 60% of zinc accretion occurs in the third trimester. Impaired intake and absorption or excess excretion can further increase this risk. Finally, periods of rapid growth, as seen in preterm infants, increase the need for zinc. Biochemically, zinc deficiency is defined by a serum zinc level less than 55mcg/dl. However, while zinc depletion is associated with deficiency, the opposite may not be true. For example, in starving patients, clinical symptoms of zinc deficiency occur during re-feeding, suggesting overall requirements are related to needs, regardless of overall zinc status. This may be the case in preterm infants, who may have a subclinical deficiency despite serum zinc level. Thus, zinc deficiency should be considered in infants with poor growth despite receiving adequate protein and calories. The objective of this study is to determine whether enteral zinc supplementation leads to improved growth in infants at risk for bronchopulmonary dysplasia (BPD). The investigator's hypothesis is that enteral zinc supplementation in very preterm infants at high risk for BPD will significantly improve growth compared to standard of care.


Recruitment information / eligibility

Status Terminated
Enrollment 37
Est. completion date August 25, 2022
Est. primary completion date May 25, 2022
Accepts healthy volunteers No
Gender All
Age group 14 Days to 28 Days
Eligibility Inclusion Criteria: 1. 23 0/7 to 29 6/7 weeks GA 2. Birth weight 501 to 1000g, inclusive 3. 14 to 28 days of life, inclusive 4. 14 day BPD risk score = 50% for death or moderate-severe BPD, calculated using the algorithm on the Neonatal Research Network website (https://neonatal.rti.org/index.cfm?fuseaction=BPDCalculator.start).- Exclusion Criteria: 1. Major congenital and/or chromosomal anomalies 2. Inability to reach 80ml/kg/day enteral feeds by 28 days of life

Study Design


Intervention

Dietary Supplement:
Zinc Acetate
Zinc Acetate given with elemental zinc dose of 2mg/kg given orally only daily through 35 6/7 weeks corrected gestational age
Other:
No supplemental zinc
Infants will receive standard of care, which is currently no supplemental zinc

Locations

Country Name City State
United States Intermountain Medical Center Murray Utah
United States University of Utah Health Salt Lake City Utah

Sponsors (2)

Lead Sponsor Collaborator
University of Utah Intermountain Research and Medical Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Growth rate for weight (g/kg/day) from birth to 36+0 weeks corrected gestational age (CGA) Average daily changes in weight from birth to 36+0 CGA will be calculated and compared between both arms. Birth to 36+0 weeks corrected gestational age
Primary Growth rate for weight (g/kg/day) from birth to 40+0 weeks CGA Average daily changes in weight from birth to 40+0 CGA (or discharge, whichever happens first) will be calculated and compared between both arms. Birth to 40+0 weeks corrected gestational age
Primary Growth rate for length (cm/week) from birth to 36+0 weeks CGA Average weekly changes in length from birth to 36+0 weeks CGA will be calculated and compared between both arms. Birth to 36+0 weeks corrected gestational age
Primary Growth rate for length (cm/week) from birth to 40+0 weeks CGA Average weekly changes in length from birth to 40+0 weeks (or discharge, whichever happens first) CGA will be calculated and compared between both arms. Birth to 40+0 weeks corrected gestational age
Primary Growth rate for head circumference (cm/week) from birth to 36+0 weeks CGA Average weekly changes in head circumference from birth to 36+0 weeks CGA will be calculated and compared between both arms. Birth to 36+0 weeks corrected gestational age
Primary Growth rate for head circumference (cm/week) from birth to 40+0 weeks CGA Average weekly changes in head circumference from birth to 40+0 weeks CGA (or discharge, whichever happens first) will be calculated and compared between both arms. Birth to 40+0 weeks corrected gestational age
Secondary Measure changes in serum insulin-like growth factor 1 (IGF-1) Differences in baseline, 28 days after study intervention initiation, and 36 weeks CGA will be compared between both arms Study day 0 to 36 weeks corrected gestational age
Secondary Measure changes in serum insulin-like growth factor binding protein 3 (IGFBP-3) Differences in baseline, 28 days after study intervention initiation, and 36 weeks CGA will be compared between both arms Study day 0 to 36 weeks corrected gestational age
Secondary Measure rates of severe BPD diagnoses at 36+0 weeks CGA Infants will be screened per the NICHD 2001 criteria for severe BPD at 36+0 weeks CGA and these rates will be compared between the two arms. 36+0 weeks corrected gestational age
Secondary Measure changes in bone quality per tibial ultrasound Differences in baseline, 28 days after study intervention initiation, and 36 weeks CGA will be compared between both arms Study day 0 to 36 weeks corrected gestational age
See also
  Status Clinical Trial Phase
Terminated NCT04506619 - Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants
Completed NCT04936477 - Ventilation-perfusion (V/Q) Ratio and Alveolar Surface Area in Preterm Infants N/A
Recruiting NCT05285345 - Implementation of a Consensus-Based Discharge Protocol for Preterm Infants With Lung Disease
Completed NCT03649932 - Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing Phase 1
Terminated NCT02524249 - Early Versus Late Caffeine for ELBW Newborns N/A
Completed NCT02249143 - Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants N/A
Active, not recruiting NCT01632475 - Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia
Completed NCT01460576 - Improving Prematurity-Related Respiratory Outcomes at Vanderbilt N/A
Unknown status NCT00254176 - Cysteine Supplementation in Critically Ill Neonates Phase 2/Phase 3
Completed NCT00419588 - Growth of Airways and Lung Tissues in Premature and Healthy Infants
Completed NCT00319956 - Trial II of Lung Protection With Azithromycin in the Preterm Infant Phase 2
Completed NCT00208039 - Pilot Trial of Surfactant Booster Prophylaxis For Ventilated Preterm Neonates N/A
Completed NCT00006401 - Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants Phase 3
Terminated NCT05030012 - Maintaining Optimal HVNI Delivery Using Automatic Titration of Oxygen in Preterm Infants N/A
Completed NCT00006058 - Study of the Pathobiology of Bronchopulmonary Dysplasia in Newborns N/A
Completed NCT00005376 - Premature Birth and Its Sequelae in Women N/A
Completed NCT00011362 - Dexamethasone Therapy in VLBW Infants at Risk of CLD Phase 3
Completed NCT00004805 - Study of the Effect of Four Methods of Cardiopulmonary Resuscitation Instruction on Psychosocial Response of Parents With Infants at Risk of Sudden Death N/A
Completed NCT05152316 - The Baby Lung Study
Recruiting NCT04821453 - NAVA vs. CMV Crossover in Severe BPD N/A